GROWTH
Top line accelerating.
+10.4% YoY versus +6.5% prior. 3y CAGR +8.5%.
+10.4%
IDEXX Laboratories, Inc. IDXX
Healthcare · Market Cap: $44.2B
Live price unavailable
Fundamentals as of 2026-03-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $44.2B
Live price unavailable
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
1 of 2 legendary models say AVOID IDXX — but Warren Buffett disagrees.
What would legendary investors pay for IDXX?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — IDEXX Laboratories, Inc.'s 70.4% ROE ranks above the S&P 500 median, and D/E 1.18 stays within healthy bounds.
Financial story
Yes — IDEXX Laboratories, Inc.'s 70.4% ROE shows strong capital efficiency, and its 1.18 debt-to-equity stays within healthy bounds.
Bottom line: IDXX splits the legendary models — 1 BUY, 0 HOLD, 1 AVOID, but earns a C sector grade (57/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
+10.4% YoY versus +6.5% prior. 3y CAGR +8.5%.
+10.4%Net margin 24.6% versus 22.8% prior (+1.8pp). Operating 31.6%.
24.6%P/E 41.5x — 13% below the 5y median of 47.9x. Forward 38.4x hints at EPS expansion next year.
41.5xIDXX is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 2 legendary investor models rate IDXX a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $537. See the per-investor fair-value table in the valuation tab.
IDXX trades at 41.3x earnings. Sector context and per-investor signals are in the valuation tab.
IDXX and ALNY differ on P/E, ROE, and revenue growth. See the full IDXX vs ALNY compare matrix.
Buffett and Munger evaluate IDXX against their respective frameworks. Per-model fair value and reasoning are in the
How does IDXX compare?
See exactly where IDXX ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingIDXX sits at #26 in Healthcare with a C grade (57/100).
